Intermountain’s Liljenquist on price transparency, insulin and having 3 brothers with diabetes | Healthcare Dive

As Intermountain Healthcare looks to upend the status quo by launching its own generic drug manufacturing firm, the health system is hoping the deal forces more transparency in the industry.

Healthcare Dive chatted with Dan Liljenquist, the man leading the charge behind Civica Rx, about the status of the nonprofit drug venture as it looks to get off the ground soon in an effort to curb drug prices, particularly for drugs that have been on the market for years.

Fed up with skyrocketing prices for generic drugs, Utah-based Intermountain and other nonprofit providers announced earlier this year they would launch their own drug manufacturing company. Recently, the group named former Amgen executive Martin VanTriste as its CEO and said it had selected the 14 hospital-administered drugs it plans to manufacture, although officials have declined to name the therapies.

Read complete article here:

Intermountain’s Liljenquist on price transparency, insulin and having 3 brothers with diabetes | Healthcare Dive.